Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study Meeting Abstract
| Authors: | Sehn, L. H.; Herrera, A. F.; Matasar, M. J.; Kamdar, M.; Assouline, S.; Hertzberg, M.; Kim, T. M.; Kim, W. S.; McMillan, A.; Ozcan, M.; Hirata, J. M.; Penuel, E.; Cheng, J.; Ku, G.; Flowers, C. R. |
| Abstract Title: | Polatuzumab vedotin (pola) plus bendamustine (B) with rituximab (R) or obinutuzumab (G) in relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Updated results of a phase (Ph) Ib/II study |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837605059 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-118551 |
| Notes: | Meeting Abstract: 1683 -- Source: Wos |
